OxDX, an Oxford, UK-based University of Oxford spin-out building instant pathogen tests using super-resolution microscopy and machine learning, raised £2.6 million in pre-seed funding for its AI-powered diagnostic technology that can recognize and identify specific strains of viruses, bacteria, and other pathogens within a sample in seconds.
The initial funding is co-led by IQ Capital and Ahren Innovation Capita,l with participation from Science Creates Ventures.
The fund will be used to expand the team and further validate the technology with development partners.
Company: OxDX Ltd.
Funding Month: February 2022
Lead Investors: IQ Capital and Ahren Innovation Capital
Additional Investors: Science Creates Ventures
Company Website: https://www.oxdx.com/
Software Category: Pathogen tests
About the Company: OxDX is a rapid pathogen detection company, a spin-out from the University of Oxford, which combines the power of single-molecule fluorescent microscopy with machine learning to identify pathogens in under a minute. OxDX's primary goal is to develop rapid diagnostics tools that enable clinicians to ask widely open questions about the causes of infection. Combine academic expertise with a strong technical and commercial history, all supported by dynamic and knowledgeable investors. OxDX uses a universal labeling system to light up everything in our sample, image the sample using super-resolution fluorescence microscopy and analyze the images in our neural network.